TransCode Therapeutics Inc (RNAZ) News

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Two patients dosed; several additional patients screened for enrollmentTrial to evaluate safety and...

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer

BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology...

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology...

Form 8-K - Current report

Form 8-K - Current report

TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation

Two clinical trial sites activatedPatient enrollment expected this quarterTrial designed to evaluate the safety...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

TransCode Therapeutics, Inc. Announces Closing of Public Offering

BOSTON, July 24, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the...

Form 424B5 - Prospectus [Rule 424(b)(5)]